reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

cute promyelocytic leukemia (APL) is a variant of AML characterized by t (15; 17). The discovery of the molecular pathogenesis has led to the first targeted therapy for acute leukemia: all-trans retinoic acid (ATRA). ATRA is usually associated to anthracycline-based chemotherapy obtaining high response rates, but some potential longterm sequelae are described [1]. The introduction of arsenic trioxide (ATO)[2] and ATRA was compared to standard chemotherapy in a pivotal trial with excellent results both in terms of complete
Lingua originaleEnglish
pagine (da-a)1328-1330
Numero di pagine3
RivistaLEUKEMIA & LYMPHOMA
Stato di pubblicazionePubblicato - 2019

Keywords

  • reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid

Fingerprint

Entra nei temi di ricerca di 'reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid'. Insieme formano una fingerprint unica.

Cita questo